Get started
Author

Erin Wuerdeman

Observed institution: NewAmsterdam Pharma (Netherlands)
ORCID: 0009-0004-2896-2452
Observed ORCID: 0009-0004-2896-2452
OpenAlex ID: A5093533626
Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
2024 · Stephen J. Nicholls, Adam J. Nelson, et al. · American Heart Journal · 47
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
2024 · Mariko Harada-Shiba, Michael H Davdison, et al. · Journal of Atherosclerosis and Thrombosis · 39
PDF
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
2026 · Stephen J. Nicholls, Adam J. Nelson, et al. · Nature Medicine · 21
A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
2024 · Jing Zhang, Guoying Cao, et al. · The Journal of Clinical Pharmacology · 7
PDF
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia
2025 · Stephen Nicholls, Adam Nelson, et al. · Journal of clinical lipidology · 2
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
2026 · Stephen J. Nicholls, Adam J. Nelson, et al. · Nature Medicine · 1
PDF
Abstract 4368890: Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials
2025 · Michael Davidson, Stephen Nicholls, et al. · Circulation · 1
Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia
2025 · Andy Hsieh, Stephen Nicholls, et al. · American Journal of Preventive Cardiology · 1
Short-term variability and threshold reclassification of Lp(a) in the placebo arms of phase 3 obicetrapib trials
2026 · Michael Szarek, Kausik K. Ray, et al. · American Journal of Preventive Cardiology
PDF
Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study Results
2026 · John Kastelein, Marc Ditmarsch, et al. · Atherosclerosis
Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study Results
2026 · John Kastelein, Marc Ditmarsch, et al. · Journal of clinical lipidology
Obicetrapib lowers LDL-cholesterol by substantially increasing LDL-ApoB clearance rates in humans
2025 · Archna Bajaj, John Millar, et al. · Journal of clinical lipidology
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins
2025 · Michael H Davidson, Mariko Harada-Shiba, et al. · Journal of clinical lipidology
Abstract 15201: Obicetrapib as an Adjunct to Stable Statin Therapy Significantly Lowers LDL-C, Non-HDL-C, and Apolipoprotein B in Japanese Patients: Results From the Japan Phase 2 Study
2023 · Mariko Harada-Shiba, Douglas Kling, et al. · Circulation
Works count: 14
Citation count: 119
H-index: 4
I10-index: 3
Year
Topic
Type